Vanguard Capital Management
LEXX icon

Vanguard Capital Management’s Lexaria Bioscience LEXX Stock Holding History

Vanguard Capital Management’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$167K Buy
19,896
+5,076
+34% +$55K ﹤0.01% 3835
2026
Q1 		$173K Buy
+14,820
New +$161K ﹤0.01% 3815

Other funds holding LEXX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management's LEXX Position: Q2 2026 in Review

Vanguard Capital Management increased its Lexaria Bioscience (LEXX) stake by 34% in Q2 2026, buying an estimated $55K and bringing the position to 19,896 shares worth $167K. The position accounts for ﹤0.01% of the portfolio, ranked #3835.

Vanguard Capital Management first reported a position in LEXX in Q1 2026 and has held it in 2 quarters since. The position peaked at $173K in Q1 2026. 27 funds tracked by Wall St. Rank hold LEXX as of Q2 2026.

  • Vanguard Capital Management held 19,896 shares of Lexaria Bioscience worth $167K as of Q2 2026.
  • Vanguard Capital Management bought 5,076 Lexaria Bioscience shares in Q2 2026, an estimated $55K.
  • Lexaria Bioscience made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3835 holding.
  • Vanguard Capital Management first reported a position in Lexaria Bioscience in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Lexaria Bioscience position peaked at $173K in Q1 2026.
  • 27 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.